Biotech funding rebounds but young startups lag behind

As of late September 2026, the biotech funding rebound is broad but uneven. Global biotech funding through August 7 climbed 75% from a year earlier, with IPO proceeds up 235% and follow-on offerings up 138%, Macquarie reported. But a separate Massachusetts industry snapshot found that early-stage startups are being shut out of much of that capital. The tension between a hot IPO market and a cold seed market frames the current boom.

MassLive reported that the life sciences workforce contracted 1% from 2023 to 2025, eliminating roughly 1,400 positions statewide, after growing every year since 2010. Employers filed WARN notices for more than 2,300 anticipated layoffs in 2025, up from about 1,400 the prior year and about 487 in 2022. MassBio's Ben Bradford said employment had slowed but added, "I don't think it's the death of the industry by any means". He and Massachusetts Life Sciences Center's Jeann LeClair saw signs of recovery: the IPO market opening, venture capital flowing, and a record number of tax incentive applications.

On August 10, Investing.com summarized Macquarie data and a cluster of large transactions. Braveheart Bio, the second company spun out of Hengrui, raised $382.5 million in an upsized Nasdaq IPO, and its shares jumped 66% in their August 6 debut. Curium struck a deal to buy Lantheus for as much as $8 billion, and Tarsus Pharma agreed to buy Alkeus Pharma for $450 million upfront plus up to $350 million in milestones. Supernus and Indivior announced an all-stock merger, and KKR agreed to take Integer private for $5.7 billion. The XBI biotech index gained 7% that week.

An August 25 MassBio report showed Massachusetts drugmakers raised nearly $3.5 billion in venture capital during the first half of 2026, up 25% from the same period in 2025, and eight Boston-area drugmakers completed initial public offerings from January through July, one of which was Parabilis Medicines, which set a sector record for IPO proceeds. But the report also found a widening gap: average seed rounds fell to $4.65 million, while mean Series A financings ballooned to nearly $80 million. MassBio's biggest concern, it said, was "the earliest startups with the riskiest science".

The report added a new "China Watch" section, finding that China's pipeline of drug candidates expanded 36.2% from the prior year and overtook Europe for the first time, while the U.S. pipeline was nearly flat and Massachusetts' climbed 9.2%. Licensing deals for China-discovered drugs generated $79 billion in proceeds last year, up from $1 billion in 2019. Bradford said companies turn to China not necessarily because of cost, but because of speed.

BioXconomy reported that EY's first-half review found $196 billion in life sciences M&A spending, a 140% jump from H1 2025. The average deal size climbed 71%, and 63% of deals involved candidates at pre-Phase III stages, up from 39% across fiscal 2025. EY's Subin Baral said the percentage of listed biotechs holding cash for no more than two years dropped to 34% in 2026 from 56% in 2025, aided by consolidation and robust venture rounds. The world's 25 largest biopharma groups must fill a combined $372 billion revenue hole by 2032, up from $21 billion a year earlier; that shortfall, the article says, is arguably the single biggest driver of the M&A acceleration.

The Financial Times published an article asking whether AI has broken the old VC model. BigGo Finance reported that Iambic Therapeutics, a drug developer using artificial intelligence and backed by Nvidia and Qatar's sovereign wealth fund, had filed registration documents for a Nasdaq IPO. Renaissance Capital estimated the offering could raise up to $100 million. Iambic's lead candidate, IAM1363, is in Phase 1/1b testing for HER2-driven solid tumors, and the filing coincided with a multi-year artificial intelligence-based drug discovery agreement with AbbVie. Renaissance Capital's Matt Kennedy noted that the five strongest IPO debuts this year among offerings of $50 million or more all came from biotech, crediting pipeline progress and active dealmaking. For young startups, though, the picture is more difficult: seed rounds are shrinking while later rounds grow, and MassBio warns the ecosystem needs renewed momentum to reach "the front end of the pipeline".